In lung, liver, breast, ovarian, and prostate cancers, fibulin-3 acts as an angiogenesis antagonist (Sadr-Nabavi et al., 2009; Hu et al., 2011; Chen et al., 2013). Here, EFEMP1 is linked to prostate carcinoma.